Aeromics

Headquarters

Flag of United States of AmericaUnited States of America

Aeromics, Inc. is a pharmaceutical company in the clinical development stage working on an intravenously administered aquaporin-4 (AQP4) inhibitor (AER-271) designed for severe, acute ischemic stroke to prevent or halt brain swelling (cerebral edema) after an ischemic event. AER-271, by averting brain swelling, is anticipated to notably enhance survival post an ischemic brain event, result in improved outcomes and quicker and complete recovery, and diminish the necessity for more intrusive treatments such as decompressive craniectomy. Currently, Aeromics is studying the pharmacokinetics, safety, and tolerability of AER-271 in a Phase 1 clinical trial.